To assess the therapeutic efficacy of prostacyclin in nonhemorrhagic cerebral infarction.
- Prostacyclin (Epoprostenol)Drug
Intervention Desc: Prostaglandin, presumed vasodilator.
Randomized, placebo-controlled, double-blind trial involving 80 patients at 5 centers.
Patients in the prostacyclin group received a continuous IV infusion of prostacyclin or placebo at an average rate of 8.5 ng/kg/min for 72 hours.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Hemodynamic changes, neurologic deficit scores as determined on admission, at Day 3, and at Weeks 1, 2, and 4.|